Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Mouth Neoplasms 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Vaccinia 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1

Interventions

Nivolumab 21cabozantinib 12Specimen Handling 11Ipilimumab 10belzutifan 9pembrolizumab 8Magnetic Resonance Spectroscopy 8CTLA-4 Antigen 5Biopsy 5Axitinib 5lenvatinib 4Sunitinib 4Immunoglobulin G 3Disulfides 3zimberelimab 2tivozanib 2relatlimab 2pazopanib 2palbociclib 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2Radiosurgery 2Nephrectomy 2Bevacizumab 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × cemiplimab × 30 days × Clear all
NCT07594106 2026-05-18

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
265 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡